| Oct 28 |
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)
|
| Oct 28 |
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
|
| Oct 28 |
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
|
| Oct 28 |
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
|
| Oct 25 |
Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs
|
| Oct 25 |
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
|
| Oct 10 |
Iterum Therapeutics to Present Data at IDWeek 2024
|
| Oct 9 |
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 24 |
Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
|
| Sep 10 |
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug
|
